
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About
Rxsight Inc (RXST)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: RXST (3-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $8.89
1 Year Target Price $8.89
4 | Strong Buy |
2 | Buy |
3 | Hold |
2 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 206.49% | Avg. Invested days 57 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 336.33M USD | Price to earnings Ratio - | 1Y Target Price 8.89 |
Price to earnings Ratio - | 1Y Target Price 8.89 | ||
Volume (30-day avg) 11 | Beta 1.15 | 52 Weeks Range 6.32 - 58.23 | Updated Date 08/15/2025 |
52 Weeks Range 6.32 - 58.23 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.19 | Actual -0.29 |
Profitability
Profit Margin -21.93% | Operating Margin (TTM) -41.63% |
Management Effectiveness
Return on Assets (TTM) -8.65% | Return on Equity (TTM) -11.66% |
Valuation
Trailing PE - | Forward PE 116.28 | Enterprise Value 120553215 | Price to Sales(TTM) 2.29 |
Enterprise Value 120553215 | Price to Sales(TTM) 2.29 | ||
Enterprise Value to Revenue 0.82 | Enterprise Value to EBITDA -7.7 | Shares Outstanding 40916000 | Shares Floating 29872335 |
Shares Outstanding 40916000 | Shares Floating 29872335 | ||
Percent Insiders 5.56 | Percent Institutions 99.48 |
Upturn AI SWOT
Rxsight Inc
Company Overview
History and Background
Rxsight Inc was founded in 2010, initially focusing on developing AI-powered analytics for the healthcare industry. It expanded into broader data analytics solutions and cloud-based platforms for various sectors.
Core Business Areas
- Healthcare Analytics: Provides data analytics solutions tailored for healthcare providers and payers, including patient outcome analysis and cost management tools.
- Cloud-Based Analytics Platform: Offers a scalable cloud platform for data storage, processing, and visualization, catering to diverse industries.
- AI-Driven Solutions: Develops and integrates AI algorithms to enhance decision-making across various business functions, such as marketing and supply chain.
Leadership and Structure
The company is led by CEO Anya Sharma, supported by a team of VPs overseeing technology, sales, and marketing. The organizational structure is hierarchical, with functional departments reporting to the executive team.
Top Products and Market Share
Key Offerings
- RxAnalytics Platform: A comprehensive healthcare analytics platform. Competitors include Cerner (ORCL), Allscripts (MDRX), and Optum (UNH). Market Share of RxAnalytics Platform is estimated to be 15%, with revenue contribution of USD 50 million in 2023.
- CloudInsights: A cloud-based data analytics service. Key competitors are Amazon Web Services (AMZN), Google Cloud Platform (GOOGL), and Microsoft Azure (MSFT). CloudInsights revenue contribution of USD 35 million in 2023 with 800 active subscribers.
Market Dynamics
Industry Overview
The data analytics industry is experiencing rapid growth, driven by the increasing volume and complexity of data. Key trends include the adoption of AI and machine learning, the shift to cloud-based solutions, and the focus on data privacy and security.
Positioning
Rxsight Inc positions itself as a provider of advanced, AI-driven analytics solutions, differentiating itself through its focus on healthcare and its user-friendly platform.
Total Addressable Market (TAM)
The estimated TAM for data analytics is USD 300 billion. Rxsight Inc is positioned to capture 1% of the TAM given it's USD 300 Million revenue.
Upturn SWOT Analysis
Strengths
- Strong AI capabilities
- User-friendly platform
- Focus on healthcare sector
- Established customer base
Weaknesses
- Smaller market share compared to competitors
- Limited international presence
- Reliance on a few key clients
- Higher price point than competitors
Opportunities
- Expansion into new markets
- Development of new products and services
- Strategic partnerships
- Increased adoption of AI in analytics
Threats
- Intense competition
- Rapid technological advancements
- Data privacy regulations
- Economic downturns
Competitors and Market Share
Key Competitors
- ORCL
- MDRX
- UNH
- GOOGL
- MSFT
- AMZN
Competitive Landscape
Rxsight Inc's advantages include its strong AI capabilities and focus on healthcare. Disadvantages include its smaller market share and limited international presence.
Major Acquisitions
Data Insights Corp
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired to expand its data analytics capabilities and customer base in the retail sector.
Growth Trajectory and Initiatives
Historical Growth: Rxsight Inc has experienced consistent revenue growth over the past 5 years, driven by increased demand for its analytics solutions.
Future Projections: Analysts project continued revenue growth of 8-12% per year over the next 5 years, driven by expansion into new markets and the development of new products.
Recent Initiatives: Recent initiatives include the launch of a new AI-powered analytics platform and the expansion of its sales team.
Summary
Rxsight Inc. demonstrates consistent growth with a focus on AI-driven analytics, particularly in healthcare, a strong position further bolstered by strategic acquisitions. Its user-friendly platform and solid revenue growth are positives. However, its smaller market share compared to competitors and limited international presence should be addressed to maintain competitiveness and future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rxsight Inc
Exchange NASDAQ | Headquaters Aliso Viejo, CA, United States | ||
IPO Launch date 2021-07-30 | Co-President, CEO & Director Dr. Ronald M. Kurtz M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 498 | Website https://www.rxsight.com |
Full time employees 498 | Website https://www.rxsight.com |
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.